Targeting potent warheads to the tumor microenvironment

Our Science

The pre|CISION® peptide drug conjugate platform. >

Partnering

Avacta is seeking to expand its partnerships for targeted cancer therapies. >

Scrip Awards

We’re delighted to be shortlisted as a finalist at the 2024 Scrip Awards in the ‘Best Oncology R&D Advance’ category >

 

AVA6000 is the first clinical-stage pre|CISION® molecule. It is a peptide drug conjugate that leverages the tumor-specific expression of FAP.

Read more